Get started
Add Flow to your clinical pathway
Mental health treatment
should be simple and accessible for everyone
Provide your patients with an effective and easy-to-use, at-home depression treatment option. Flow has a favourable side effect profile and can be used as a standalone intervention or in combination with other treatment approaches.
Join more than 500 private practice clinics and 5 NHS trusts and build Flow into your depression treatment pathway.
Certified in the UK, EU and USA
Switzerland, Norway, Hong Kong, Chile, UAE and Australia
Flow has regulatory approval for use as a Class IIa medical device across
- UK (UKCA, MHRA)
- EU (CE marking under EU MDR 2017/745 from its Notified Body BSI)
- USA (FDA Class III PMA)
- Australia (TSA)
- UAE (MOHAP)
Pilots in 5 NHS Trusts and NHS Practitioner Health
Approved by the British Standards Institutions (BSI)
Class IIa medical device CE-marked
Tested according to IEC 60601 for electrical medical device safety
Results at 10 weeks from a multisite, double-blind placebo-controlled randomised superiority trial were statistically significant for both primary and secondary endpoints.
Flow achieved a 57.5% remission rate using the MADRS scale and was effective as both standalone and adjunctive therapy1.
References: 1. Woodham, R.D., Selvaraj, S., Lajmi, N. et al. Nat Med (2024). 2. Data on file. Flow Neuroscience Real-world reports. 2025.